Lucid Diagnostics (LUCD) Stock Price, News & Analysis

Company Overview

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on detecting esophageal precancer and cancer at an earlier, more treatable stage. The company is a subsidiary of PAVmed Inc. and develops diagnostic products intended to help identify patients at risk for esophageal adenocarcinoma, a cancer associated with Barrett’s esophagus and chronic gastroesophageal reflux disease.

Lucid’s primary products are EsoGuard, a laboratory-developed DNA test, and EsoCheck, a noninvasive, swallowable balloon device used to collect cells from the esophagus. Together, the products are designed to support screening of patients with chronic reflux or other risk factors who may not otherwise undergo traditional endoscopic evaluation. Testing is performed through Lucid’s laboratory operations in the United States.

The company was established to commercialize technologies developed for earlier detection of esophageal disease and has focused its activities primarily on the U.S. market. Lucid Diagnostics is headquartered in New York and operates as part of the PAVmed group of medical technology companies.

Key Stats

• Today's Range: $0.47 to $0.53
• 50-Day Range: $0.48 to $1.01
• 52-Week Range: $0.47 to $1.63
• Volume: 2.33 million shs
• Average Volume: 1.90 million shs
• Market Capitalization: $97.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.19
• Consensus Rating: Moderate Buy

Lucid Diagnostics Stock Analysis - MarketRank™

Lucid Diagnostics scored higher than 44% of companies evaluated by MarketBeat, and ranked 648th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Lucid Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Lucid Diagnostics has a consensus price target of $4.19, representing about 776.0% upside from its current price of $0.48.

Amount of Analyst Coverage

Lucid Diagnostics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lucid Diagnostics are expected to grow in the coming year, from ($0.23) to ($0.18) per share.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.11% of the float of Lucid Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Lucid Diagnostics has a short interest ratio ("days to cover") of 10.32, which indicates bearish sentiment.

Change versus previous month

Short interest in Lucid Diagnostics has recently increased by 4.87%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lucid Diagnostics does not currently pay a dividend.

Dividend Growth

Lucid Diagnostics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: N/A

News Sentiment

Lucid Diagnostics has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Lucid Diagnostics this week, compared to 2 articles on an average week.

Search Interest

Only 6 people have searched for LUCD on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

MarketBeat Follows

2 people have added Lucid Diagnostics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lucid Diagnostics insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.90% of the stock of Lucid Diagnostics is held by insiders.

Percentage Held by Institutions

74.01% of the stock of Lucid Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/16/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LUCD
• CIK: 1799011
• Web: www.luciddx.com
• Phone: 212-949-4319
• Fax: N/A
• Employees: 82
• Year Founded: 1991

Price Target and Rating

• Average Price Target for Lucid Diagnostics: $4.19
• High Price Target: $9.25
• Low Price Target: $2.00
• Potential Upside/Downside: +776.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$58.01 million
• Net Margins: -959.76%
• Pretax Margin: -959.76%
• Return on Equity: N/A
• Return on Assets: -119.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.33
• Quick Ratio: 1.31

Sales & Book Value

• Annual Sales: $4.71 million
• Price / Sales: 20.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.31) per share
• Price / Book: -1.54

Miscellaneous

• Outstanding Shares: 203,240,000
• Free Float: 189,220,000
• Market Cap: $97.15 million
• Optionable: No Data
• Beta: 1.12